Re: Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
Author:
- Alan J. WeinAWAlan J. Wein
- 30 June 2013
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (6) , 2204-2205